文献速递艾滋病与性传播感染

匹伐他汀对HIV感染者表观遗传衰老标志物的影响:REPRIEVE试验的初步子研究

Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究为REPRIEVE试验的初步子研究,纳入99名接受抗逆转录病毒治疗的HIV感染者,随机分配至匹伐他汀组(65人)或安慰剂组(34人),评估24个月时表观遗传衰老标志物的变化。结果显示,基线时所有参与者均存在表观遗传年龄加速;

要点

  • HIV感染者基线时普遍存在表观遗传年龄加速,中位差值7.08年。
  • 匹伐他汀组24个月DunedinPACE衰老速度未增加,安慰剂组增加。
  • PCGrimAge在两组间无显著差异,需进一步研究他汀对衰老的干预作用。

核心结论

  • 在REPRIEVE试验的初步子研究中,匹伐他汀可能预防HIV感染者生物学衰老速度的增快。

研究设计与样本

  • 研究为REPRIEVE试验的初步子研究,随机选取99名美国REPRIEVE参与者(65名匹伐他汀,34名安慰剂),在基线和24个月时利用外周血单核细胞DNA甲基化谱评估表观遗传衰老标志物。

主要发现

  • 基线中位实际年龄为57.0岁(Q1,Q3:56,58),所有参与者均存在表观遗传年龄加速,PCGrimAge与实际年龄中位差值为7.08年(Q1,Q3:4.69,9.64)。

临床怎么用

  • 对于接受抗逆转录病毒治疗且传统心血管风险低至中度的HIV感染者,匹伐他汀可能有助于减缓生物学衰老速度,但需进一步研究证实。

局限性

  • 本研究为初步子研究,样本量较小(共99人),结果需在更大规模研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with human immunodeficiency virus (HIV, PWH) exhibit increased cardiovascular disease (CVD) risk and accelerated biological aging. REPRIEVE demonstrated that pitavastatin reduced major adverse cardiovascular events (MACE) in antiretroviral therapy (ART)-treated PWH with low-to-moderate traditional cardiovascular risk. It remains unknown whether statin therapy can modulate epigenetic aging in PWH. METHODS: We assessed epigenetic aging biomarkers using DNA methylation profiles from peripheral blood mononuclear cells (PBMCs) in a subset of 99 randomly selected US REPRIEVE participants (65 pitavastatin, 34 placebo) at baseline and 24 months. The primary outcomes were changes in second- and third-generation epigenetic clocks PCGrimAge (trained on mortality risk) and DunedinPACE (trained on rate of age-related multi-organ decline). RESULTS: Median chronological age was 57.0 (Q1, Q3: 56, 58) years and 100% of participants demonstrated epigenetic age acceleration, measured by the difference in PCGrimAge and chronological age (median difference 7.08 years [Q1, Q3: 4.69, 9.64]) at entry. Over 24 months, PCGrimAge remained accelerated with no significant differences between treatment arms (P = .89). However, the median pace of aging by the DunedinPACE increased in the placebo arm (0.036, Q1, Q3 [-0.018, 0.10], P = .021) but not in the pitavastatin arm (0.001, Q1, Q3 [-0.031, 0.036], [P = .77]), treatment group difference (P = .049). CONCLUSIONS: In this pilot study of REPRIEVE, epigenetic age acceleration was demonstrated at trial entry. The biological pace of aging increased over 24 months in the placebo group as compared to the statin group. These preliminary findings suggest pitavastatin may prevent an increase in the pace of biological aging in PWH and support further research into statin therapy as a potential intervention to mitigate accelerated aging. CLINICAL TRIALS REGISTRATION: NCT02344290 (date of initial registration: 22 January 2015).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Corley MJ, Watanabe M, Pang APS, et al. Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial. Clin Infect Dis. 2026. PMID: 40576558. doi:10.1093/cid/ciaf247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。